Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

MLA

Teng Li, et al. “Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations.” Thoracic Cancer, vol. 12, no. 21, Nov. 2021, pp. 2924–32. EBSCOhost, https://doi.org/10.1111/1759-7714.14156.

APA

Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xingsheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, & Junling Li. (2021). Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer, 12(21), 2924–2932. https://doi.org/10.1111/1759-7714.14156

Chicago

Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xingsheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, and Junling Li. 2021. “Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations.” Thoracic Cancer 12 (21): 2924–32. doi:10.1111/1759-7714.14156.